EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer

Denis Mesinovic, Johannes Bobjer, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Henrik Kjölhede, Per-Uno Malmström, Viveka Ströck, Karin Söderkvist, Anders Ullén und 3 weitere

Scandinavian Journal of Urology · 17.04.2026 · 61 · 127-130

DOI: 10.2340/sju.v61.45712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Urology, online erschienen am 17.04.2026. Verfasst von Denis Mesinovic und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology Skåne University Hospital, Malmö, Sweden. denis.mesinovic…. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Neoplasm Recurrence, Local, Urinary Bladder Neoplasms. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Bladder Cancer Group (IBCG) has proposed a prognostic model for intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) for clinical decision-making. We applied the IBCG IR model in a population-based Swedish setting in patients with primary IR NMIBC diagnosed 2013–2014 in BladderBaSe 2.0. Patients were stratified into low-risk (unifocal and tumour size < 3 cm) and intermediate-risk (multiple and/or tumour size ≥ 3 cm) for estimation of 1- and 3-year recurrence-free survival (RFS). Among 710 patients with IR NMIBC, 329 (46%) and 381 (54%) were categorized as low- and intermediate-risk, respectively. Probabilities of disease recurrence or death at 1 and 3 years in low-risk patients were 19% (95% confidence interval [CI]: 15–23) and 41% (95% CI: 35–46), versus 27% (95% CI: 22–31) and 45% (95% CI: 40–50) in the intermediate-risk group. In a sensitivity analysis including only patients receiving serial adjuvant instillations (n = 152) the corresponding probabilities at 1 and 3 years were 19% (95% CI: 10–28) and 33% (95% CI: 22–43) versus 15% (95% CI: 7–23) and 31% (95% CI: 20–41), respectively. Thus, no clinically meaningful difference in recurrence-free survival was observed between International Bladder Cancer Group low- and intermediate-risk groups in this population-based primary non-muscle invasive bladder cancer setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsHumansFemaleDisease-Free SurvivalAgedMaleRisk AssessmentMiddle AgedSwedenAged, 80 and overPrognosis

Autor:innen und Institutionen

  • Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology Skåne University Hospital, Malmö, Sweden. denis.mesinovic@med.lu.se.
  • Department of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology Skåne University Hospital, Malmö, Sweden.
  • Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Department of Clinical and Experimental Medicine, Division of Urology, Linköping University, Linköping, Sweden.
  • Department of Urology, Danderyd Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
  • Department of Urology, School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Zitieren

APA

Mesinovic, D., Bobjer, J., Hagberg, O., Aljabery, F., Gårdmark, T., Jahnson, S., Jerlström, T., Kjölhede, H., Malmström, P. U., Ströck, V., Söderkvist, K., Ullén, A., Holmberg, L., Häggström, C., & Liedberg, F. (2026). Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer. Scandinavian Journal of Urology, 61, 127-130. https://doi.org/10.2340/sju.v61.45712

Vancouver

Mesinovic D, Bobjer J, Hagberg O, Aljabery F, Gårdmark T, Jahnson S, et al. Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer. Scandinavian Journal of Urology. 2026;61:127-130. doi:10.2340/sju.v61.45712

BibTeX
@article{Mesinovic2026,
  author = {Mesinovic, Denis and Bobjer, Johannes and Hagberg, Oskar and Aljabery, Firas and Gårdmark, Truls and Jahnson, Staffan and Jerlström, Tomas and Kjölhede, Henrik and Malmström, Per-Uno and Ströck, Viveka and Söderkvist, Karin and Ullén, Anders and Holmberg, Lars and Häggström, Christel and Liedberg, Fredrik},
  title = {Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer},
  journal = {Scandinavian Journal of Urology},
  year = {2026},
  volume = {61},
  pages = {127--130},
  doi = {10.2340/sju.v61.45712}
}
Kostenlos starten →